|
|
|
|
|
|
|
Highlights from the 2022 European Society of Medical Oncology Annual Meeting |
|
|
|
|
|
Proffered Paper Session 1: GU Tumors, Prostate
|
|
| Clinical Qualification of Transcriptome Signatures for Advanced Prostate Cancer Starting ADT with or Without Abiraterone Acetate and Prednisolone: An Ancillary Study of the STAMPEDE AAP Trial
|
| Marina Parry, MD
|
| Marina Parry discussed an ancillary study of the STAMPEDE trial assessing clinical qualification of transcriptome signatures for advanced prostate cancer starting ADT with or without abiraterone acetate and prednisolone. Exploratory analysis reveals different signatures are prognostic in M1 and M0, with an interaction with metastatic stage observed in immune related signatures. |
|
|
|
|
|
| Comparison of Abiraterone Acetate and Prednisolone or Combination Enzalutamide + Abiraterone Acetate and Prednisolone for mHSPC Starting ADT: OS Results of 2 Randomized Phase III Trials from the STAMPEDE Protocol |
| Gerhardt Attard, MD, Ph.D. |
| In this presentation, Gerhardt Attard discussed a comparison of abiraterone acetate and prednisolone or combination enzalutamide + abiraterone acetate and prednisolone for mHSPC starting ADT. Enzalutamide + abiraterone acetate and prednisolone need not be combined for mHSPC (nor for high-risk localized prostate cancer). Clinically important improvements in OS when adding abiraterone acetate and prednisolone to ADT are maintained at 7 years. |
|
|
|
|
|
| Additional Insights from the STAMPEDE Trial Platform |
| Elena Castro, MD |
| Elena Castro discussed two key studies from the STAMPEDE trial platform, including “Comparison of abiraterone acetate and prednisolone or combination enzalutamide + abiraterone acetate and prednisolone for mHSPC starting ADT: OS results of 2 randomized Phase III trials from the STAMPEDE protocol” presented by Dr. Gerhardt Attard, and “Clinical qualification of transcriptome signatures for advanced prostate cancer starting ADT with or without abiraterone acetate and prednisolone: an ancillary study of the STAMPEDE AAP trial” presented by Dr. Marina Parry. |
|
|
|
|
|
|
|
|
|
|
| Biomarker Analysis and Updated Results from the Phase III PROpel Trial of Abiraterone and Olaparib vs Abiraterone and Placebo as First-Line Therapy for Patients with mCRPC |
| Fred Saad, MD, FRCS |
| Fred Saad discussed a biomarker analysis and updated results from the Phase III PROpel trial of abiraterone and olaparib vs abiraterone and placebo as first-line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). Results from PROpel continue to support a superior clinical benefit with abiraterone + olaparib versus abiraterone + placebo as first-line therapy for patients with mCRPC. |
|
|
|
|
|
| PRESTO: A Phase 3, Open-Label Study of Androgen Annihilation in Patients with High-Risk Biochemically Relapsed Prostate Cancer (AFT-19) |
| Rahul Aggarwal, MD |
| Rahul Aggarwal discussed the PRESTO trial, a phase 3, open-label study of androgen annihilation in patients with high-risk biochemically relapsed prostate cancer. This study evaluated if intensification of ADT prolongs biochemical progression-free survival in biochemically relapsed prostate cancer, enabling longer treatment-free intervals within a framework of intermittent therapy. |
|
|
|
|
|
| Discussion of PRESTO in High-Risk Biochemically Relapsed Prostate Cancer and PROpel in mCRPC |
| Johann de Bono, MD, MSc, PhD, FRCP, FMedSci |
| Johann De Bono discussed two key studies including “PRESTO: A Phase 3, Open-Label Study of Androgen Annihilation in Patients with High-Risk Biochemically Relapsed Prostate Cancer (AFT-19)” presented by Dr. Rahul Aggarwal and “Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone and olaparib vs abiraterone and placebo as first-line therapy for patients with mCRPC” presented by Dr. Fred Saad. |
|
|
|
|
|
|
|
| Lutetium-177-PSMA Therapy in Patients with Prior Radium-223: Safety and Effectiveness Outcomes in the RALU Study |
| Kambiz Rahbar, MD |
| Kambiz Rahbar discussed safety and effectiveness outcomes of 177Lu-PSMA therapy in patients with prior treatment with radium-223. Incorporation of radium-223 in common therapy sequences for mCRPC is feasible, including taxane-based chemotherapy in between radium-223 and 177Lu-PSMA, without alteration of safety profile or overall survival from the start of 177Lu-PSMA. |
|
|
|
|
|
|
|
|
|
|
| Alkaline Phosphatase Decline and Pain Response as Markers for OS in Patients with mCRPC Treated with Radium-223 in the REASSURE Study
|
| Joe O'Sullivan, MD FRCPI, FFRRSCI, FRCR
|
| The 2022 European Society of Medical Oncology annual meeting featured a prostate cancer session, including a presentation by Joe O'Sullivan discussing alkaline phosphatase decline and pain response as markers for overall survival in patients with metastatic castration-resistant prostate cancer treated with radium-223 in the REASSURE study.
|
|
|
|
|
|
| Effect of Abiraterone-Prednisone in mCSPC with Neuroendocrine and Very High-Risk Features in the PEACE-1 Trial
|
| Alice Bernard-Tessier, MD
|
| Alice Bernard-Tessier discussed the results of the PEACE-1 trial, specifically the effect of abiraterone-prednisone in metastatic castration-sensitive prostate cancer (mCSPC) with neuroendocrine and very high-risk features. This study reviewed local pathological reports (biopsy site, WHO pathological classification, chromogranin A, and synaptophysin immunohistochemical staining) from patients randomized in PEACE-1.
|
|
|
|
|
|
| Quality of Life Across Three Countries Using a Large-Scale, Fully Digital Survey of Patients With Prostate Cancer
|
| Joe O'Sullivan, MD FRCPI, FFRRSCI, FRCR
|
| In this presentation, Joe O'Sullivan discussed the quality of life across three countries using a large-scale, fully digital survey of patients with prostate cancer. Self-reported quality of life in patients with prostate cancer did not vary substantially by country though treatment strategies differ. Quality of life was significantly affected by M+ status and comorbidity burden.
|
|
|
|
|
|
| CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk mHSPC
|
| Rana R. McKay, MD
|
| The 2022 European Society of Medical Oncology annual meeting featured a prostate cancer session, including a presentation by Dr. Rana McKay discussing the trial protocol for CYCLONE 3, a phase 3, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone + prednisone in men with high-risk metastatic hormone-sensitive prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
|
